<DOC>
	<DOCNO>NCT00957216</DOCNO>
	<brief_summary>This Physician-sponsored pilot study , whose purpose determine high-dose oral Coenzyme Q10 ( CoQ10 ) safe tolerated patient sporadic form adult-onset spinocerebellar ataxia ( SAOA ) , group degenerative neurological disorder affect cerebellum pathway cerebellum , without additional central nervous system ( CNS ) manifestation , absence family history degenerative ataxia .</brief_summary>
	<brief_title>Coenzyme Q10 Adult-Onset Ataxia</brief_title>
	<detailed_description>This Physician-sponsored pilot study , whose purpose determine high-dose oral Coenzyme Q10 ( CoQ10 ) safe tolerated patient sporadic form adult-onset spinocerebellar ataxia ( SAOA ) , group degenerative neurological disorder affect cerebellum pathway cerebellum , without additional central nervous system ( CNS ) manifestation , absence family history degenerative ataxia . CoQ10 essential cofactor electron transport chain potent free radical scavenger lipid mitochondrial membrane . CoQ10 show efficacy treatment Parkinson 's disease patient , Huntington 's disease trial give trend slow disease progression ( CARE-HD ) . A small trial CoQ10 patient Friedreich 's ataxia suggest potential beneficial effect ventricular thickness . CoQ10 test ALS patient consider potentially useful treatment Alzheimer 's disease . Thus , CoQ10 consider promising therapeutic agent might slow disease progression wide variety neurodegenerative disorder . To date , high dos CoQ10 use patient ataxia safety tolerability group patient establish efficacy trial launch . Twenty patient SAOA recruit double-blind , randomize , placebo-controlled , multicenter study . Fifteen patient receive total 2400 mg oral CoQ10 daily , five patient receive placebo , period 4 week . Cerebellar function measure use validate rating scale ( SARA ) , oculomotor examination , functional measurement motor function use 9 hole peg test time walk . Safety lab collect digital movie record beginning ( prior treatment CoQ10 ) end study .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>1 . Diagnosis SAOA 2 . Age 18 old 3 . Adult onset ataxia 4 . Ambulatory capability ( without assist device ) 5 . Women 2 year post menopause surgical sterility practice adequate birth control 6 . Stable dos psychotropic drug 7 . Stable dos drug movement disorder 8 . Ability give inform consent 9 . Ability comply trial procedure 10 . Able take oral medication 11 . No active significant systemic disease ( cardiac , pulmonary , hepatic , renal disease cancer ) adequate medical control 12 . Women childbearing potential negative urine pregnancy test practice adequate contraception study 1 . A history know sensitivity intolerability Coenzyme Q10 2 . Diagnosis secondary ( nondegenerative ) ataxia 3 . Family history degenerative ataxia 4 . Diagnosis childhoodonset ataxia 5 . DNA diagnosis inherit ataxia absence family history 6 . Other investigational agent within 30 day screen 7 . Ingestion Coenzyme Q10 within 120 day baseline visit 8 . Diagnosis ongoing malignancy 9 . Women pregnant lactate child bear potential use effective birth control 10 . Uncontrolled hypertension 11 . Symptomatic orthostatic hypotension 12 . Uncontrolled diabetes mellitus 13 . Untreated thyroid disease 14 . Major psychiatric disease within 12 month screen 15 . History noncompliance therapy 16 . Drug alcohol abuse within 12 month screen 17 . Other condition therapy may prevent participation opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>adult onset ataxia</keyword>
</DOC>